SynthesisMedicina (Kaunas, Lithuania)2021
Efficacy and Safety of Sugammadex for the Reversal of Rocuronium-Induced Neuromuscular Blockade in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
Synthesis in Medicina (Kaunas, Lithuania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Safety and Efficacy of 4 mg·kg⁻¹ Sugammadex for Simultaneous Pancreas-Kidney Transplantation Recipients: A Prospective Randomized Trial.Annals of transplantation · 2023Trial
- Impact of Sugammadex on Clinical and Patient-Centered Outcomes: Beyond Neuromuscular Recovery.Journal of clinical medicine · 2026Review
- In-depth exploration of sugammadex and novel neuromuscular blockade antagonists: a narrative review.Frontiers in pharmacology · 2026Review
- Clinical application of sugammadex in renal impairment: pharmacokinetics and pharmacodynamics.Frontiers in pharmacology · 2026Review
- Sugammadex for Neuromuscular Blockade Reversal: A Narrative Review.Journal of clinical medicine · 2025Review
- Current evidence on the use of sugammadex for neuromuscular blockade antagonism during electroconvulsive therapy: a narrative review.Korean journal of anesthesiology · 2025Review
- Residual Neuromuscular Block Remains a Safety Concern for Perioperative Healthcare Professionals: A Comprehensive Review.Journal of clinical medicine · 2024Review
- [Anesthesia for organ transplant patients].Die Anaesthesiologie · 2023Review
- Reply to the Commentary on "An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant".Anaesthesiology intensive therapy · 2023Article
- Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations.Anesthesia and pain medicine · 2023Review
- Unexpected delayed reversal of rocuronium-induced neuromuscular blockade by sugammadex: A case report and review of literature.World journal of clinical cases · 2022Article
- Response to "A novel use of neostigmine reversal for intraoperative neural monitoring during thyroid surgery".The Kaohsiung journal of medical sciences · 2022Article
- Choice of neuromuscular block reversal agent to reduce postoperative pulmonary complications.Anesthesia and pain medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.